由于试验结果和监管问题不一致, 特雷克斯公司削减了其在生物技术公司Adverum的股权. Trexquant cut its stake in biotech firm Adverum amid mixed trial results and regulatory concerns.

截至2025年9月21日,大量投资伙伴减少了对Adverum生物技术的股份,Adverum生物技术是一家生物制药公司,根据监管文件开发眼病基因疗法。 As of September 21, 2025, Trexquant Investment Partners reduced its stake in Adverum Biotechnologies, a biopharmaceutical company developing gene therapies for eye diseases, according to regulatory filings. 未披露削减的确切规模。 The exact size of the reduction was not disclosed. 这一行动遵循临床试验结果和监管审查的混合结果,反映出更广泛的投资者对高风险生物技术公司持谨慎态度。 The move follows mixed clinical trial results and regulatory scrutiny, reflecting broader investor caution toward high-risk biotech firms. 在下班后交易中,ADVM股份略有下降。 ADVM shares dipped slightly in after-hours trading. 投资者们正在观察即将作出的监管决定和试验数据,以进一步了解公司的前景。 Investors are watching upcoming regulatory decisions and trial data for further insight into the company’s prospects.